DOCSLIB.ORG

(APV),66 2-Amino-7-Phosphonoheptanoic Acid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(APV),66 2-Amino-7-Phosphonoheptanoic Acid 281 INDEX 2-amino-5-phosphono valeric acid audiogenic seizures, 3, 116, 117, 119, 121, (APV),66 122, 123, 124, 125, 126 2-amino-7-phosphonoheptanoic acid augmentation, 157 (2-APH), 131, 135 augmenting rhythms, 10 2-aminophosphonovaleric acid, 139 aura, 258 4-aminopyridine, 170 auto-spectral, 39 AAMI analysis, 53 average amount of mutual information, 49 absence seizures, 74, 80, 103, 113,240 axonal block, 224 absinthe, 240 accommodation, 65,66 beta-receptor, 66 acetylcholine, 59, 65 backfiring, 60 ACh,60,170 baclofen, 64 acidosis, 214 barbiturate-picrotoxin receptors, 172 active zones, 158 barbiturates, 234 adenosine diphosphate (ADP), 214 basal ganglia, 128 adenosine triphosphate (ATP), 205, bemegride, 121 208,211,212 benign rolandic epilepsy, 24 afterdischarge, 5, 85, 86 benzodiazepine receptor, 172 afterhyperpolarizations, 59, 222, 232 benzodiazepines, 172, 177,234 albutoin, 242 bicuculline, 66, 93, 103, 112, 113, 115, 128, alumina focus, 3, 21, 200 130, 131, 134, 135, 137, 138, 139, 140, 170, Ammon's horn, 32 206,211,212,213,214,215,216 amygdala, 23, 32, 85, 96, 124, 126, 140, bilateral onset, 31 142,257,265,267,268 bioequivalence requirements, 243 amygdala kindled seizures, 116, 119, brain stem, 102 123, 126, 128, 134, 138 Bravais-Jacksonian seizures, 272 amygdalo-hippocampectomy, 32 bromine,239 angular bundle, 91 bulbospinal system, 105 anterior commissure, 79 burst-generating behavior, 58 anterior medial thalamus, 104 bursts, 21 anterior neocortex, 86 anterior thalamic nuclei, 103, 127 cadmium, 188 antiabsence drugs, 4 calcium, 156, 157, 158 Antiepileptic Drug Development calcium activated K currents, 57, 65, 66, 171, (ADD),243 175 archicortex, 31, 259, 260 calcium binding, 157 area tempestas (AT), 134, 135, 137, 138, calcium channels, 155,222,234 139, 142, 143 calcium conductance, 232, 234 arsenazo III, 157 calcium diffusion, 157 artifact rejection, 52 calcium entry blocker, 248 aspartate, 80, 90, 92, 134 calcium influx, 157 association cortex, 259 calcium uptake, 234 atypical absences, 6 callosal pathway, 258 282 Index calmodulin, 159 dendritic domains, 10 calpain, 159 dendritic spines, 10, 159 carbachol, 86, 134 dentate gyrus, 124 carbamazepine,95,224,234,242,244 2-deoxyglucose(2CK;),4, 93, 103, 128,206, caudal medial hypothalamus, 104 256 caudate nudeus, 125 F-deoxyglucose uptake, 207 caudate putamen, 86 depolarizing shift, 170, 184 centrencephalic, 73, 101 depression, 153, 154 cerebellum, 86, 102, 103, 119 depth electrodes, 19, 258 cerebral glucose consumption, 206 desensitization, 62, 64, 155, 173, 177 cerebral oxygen utilization, 207 diazepam, 240 cerebral acidosis, 213, 214 diencephalon, 102 cerebral blood flow, 205, 206 digital filtering, 39, 52 cerebral phosphocreatine (PCr), disinhibition, 132 205,212 dopamine, 102 CGS-9896, 249 DPH, 224, 225, 227, 229 cholecystokinin, 172 dual synaptic hypothesis, 177 chronic epileptic focus, 176 dynorphin, 131 cingulate gyrus, 19,32,257 CI,76 electroconvulsive shock treatment, 7 Cl channels, 171 electrocorticography, 262 Cl conductance, 64 electrogenic ion pumps, 57 Cl equilibrium potential, 173 electrogenic Na/K pumping, 194, 200 Cl gradient, 59 electroshock seizure, 93, 101, 112, 113, 114, Cl transport, 62 206 donazepam, 242 electroshock seizure threshold, 114,240 donic convulsions, 85, 93, 112, 113, 115, electrotonic coupling, 189, 191 119,123,134 energetic change, 44 dorazepate dipotassium, 242 energetic change detection, 40 cobalt focus, 3, 21, 60, 120,200 entorhinal cortex, 86, 88, 89, 95, 123, 142,256 coherence analysis, 32, 51, 40, 53 entorhinal kindling, 96 coherence spectrum, 44 ephaptic, 61 colchicine, 88 ephaptic interactions, 57, 189, 191, 192, 193, commissural projections, 79, 142 223 complex partial seizures, 31 epidural, 19 compressed spectral array, 52 epilepsia partialis continua, 274 computer-aided methods, 52 epileptic bursts, 23 corpuscallosum,79 epileptic focus, 2 cortical mapping, 270 epileptic fowl, 3 cortical spindling, 10 epileptiform discharge, 120 cortical synaptic inhibition, 169 epileptogenic lesion, 2 corticoreticular, 73 epileptogenic zone, 2, 6, 143 creatine kinase, 214 EPSP, 76, 153 cross-spectral analysis, 39 EST, 123 current source density analysis, 40 eterobarb, 249 cytosolic pH, 208 ethanol withdrawal, 128 ethosuximide, 103 deafferented, 5 experiential phenomena, 265 decerebrate, 121 extracellular ionic concentrations, 57 deep prepiriform cortex, 139, 143 extracellular potassium, 58, 174,222 Index 283 extracellular space, 61 genetically epilepsy prone gerbils, 128 extracranial EEG, 17 gerbil,3 globus pallidus, 86, 103, 125, 126 fa~tation, 155, 156, 157,228 glucose, 205, 216 fast Fourier transform (FFf), 44 glutamate, 59, 80, 92, 134 FDG-PET, 272 glutamate receptor, 66 feed-forward,78 glutamic acid decarboxylase, 171 Felbamate, 247 glycine, 171, 173 feline generalized penicillin epilepsy glycolysis, 207 (FGPE), 73, 74, 75, 77, 79 Golgi, 5 ferric chloride, 3 granule cells, 91, 124 FFf,53 18F-fluorodeoxyglucose (FDG), 4 H-fields of Forel, 126 Flunarizine,248 heteromodal association cortex, 264 flurothyl, 117, 122, 123, 124, 126, higher-order coherence analysis, 40 128,206 hippocampal cortex, 260 Fluzinamide, 247 hippocampal formation, 257 focal origin, 31 hippocampal sc1erosis, 25, 267 focal epilepsy, 169 hippocampal slice, 67, 184 focal epileptiform discharge, 120 hippocampus,61, 62, 88,89,96, 124, 140, fodrin,159 169,191 Food and Drug Administration homocysteic, 90 (FDA),241 homocysteine, 206 forced vocalization, 274 human focal epilepsy, 176 fornices,103 human hippocampus, 5, 32 frequency faciIitation, 175 5-hydroxytryptamine, 119 frequency potentiation, 170, 224 6-hydroxydopamine, 119 frontal cortex, 257 hypermetabolism, 6 furosemide, 62 hypersynchrony,52 hypoexcitabiIity, 95 y-vinyl GABA (GVG), 93, 102, 104, 116, hypolarization, 22 128,135,137,139,249 hypometabolic zones, 272 GABA, 5, 57, 60, 102, 128,132, 171 hypometabolism, 4, 6 GABA, agonists 246 hypothalamus, 127 GABA, antagonists 133 hypoxic,64 GABA, release 62 GABA-mediated synapses, 59, 92, 170, ictal EEG onsets, 10 172 ictal hypermetabolism, 8 GABA/benzodiazepine receptor, 245 infantile spasms, 4 GABAA receptors, 64, 171 inferior cerebellar pedunc1e, 122 GABAB receptors, 64, 175, 177 inhibitory postsynaptic potentials (IPSPs), GABAergic drugs, 128 62,171,172 GAD,5 inhibitory mechanisms, 192 gamma hydroxybutyrate, 7 inhibitory seizures, 8 gap junctions, 191 initial foci, 51 generalized seizures, 112 initial locus, 43 genetic,23 initiation, 39 genetic animal epilepsies, 3 inorganic phosphate, 208 genetic predispositions, 7 insular, 260 genetically epilepsy prone rat, 3 interictal bursts, 188, 194 284 Index interictal spikes, 23, 183 mammillothalamic tracts, 103 intracellular pH, 205 massa intermedia, 79 intracranial EEG, 17 Mauthner ceIl, 173 intracranial electrodes, 19 maximal electroshock seizure (MES), intra laminar thalamic nuc1ei, 101, 127 104,114,119,121,122,123,128,130, ion pump, 199,200 131, 134, 137,139,240 ion-sensitive microelectrodes, 58 maximal electroshock test--seizure spread, iron, 21 244 ischemic, 64 medial frontal lobes, 268 isoniazid, 133 medial temporal-limbic structures, 264 medial thalamic nuc1ei, 125 Jacksonian march, 31 memory, 154 mephobarbital, 240 [Klo accumulation, 189, 192, 193 mesial temporal seizures, 7, 19 K conductance, 64 mesocortex, 259 K outward currents, 76 metenkephalin, 131 K-sensitive electrodes, 222 mexiletine, 242 kainic acid, 103, 116, 134 Mg,66 kappa opiate receptors, 131 mid hippocampi, 268 kindling, 3, 10, 33, 47, 51, 67, 85, 101, midbrain reticular formation (MRF),115 113,122,142,224,244 midbrain tegmentum, 127 Milacemide, 249 lactate, 205, 206, 207, 212, 213, 214, 215, miniature EPSP frequency, 156 216 minimal electroshock seizures, 124 Lamotrigine, 248 morphine sulfate, 130 lateral geniculate nuc1eus, 126 mu opiate receptors, 131 lateral temporal neocortex, 31 muscarinic receptor, 65 Lennox-Gastaut syndrome, 6 muscimol, 93, 94,102,103,125,128, 129, 133, lidocaine, 206 135, 139 limbic epilepsy, 27, 85, 94 mutual information analysis, 40 limbic structures, 31,113,259 linear coupling, 46 N-acetyl aspartate (NAA), 208 linear correlation, 51 N-methyl-D-aspartate (NMDA), 66, 92, lithium, 200 94, 126, 134, 140, 170, 173, 175, 177 local cerebral metabolie rate for glucose Na channel, 222, 224, 225, 232 (LCMRGlu),4 Na conductance, 234 locus coeruleus, 119 Na-K ATPase, 200 long term potentiation (LTP), 32, 89, 91, Na-K pump, 59, 64 153,154,158,224 Nafimidone, 247 low Ca seizures, 184 naloxone, 131 low frequency electroshock threshold, nasopharyngeal, 17 114 neocortex, 31, 103, 169 neocortical brain slice, 22 M-current, 65 neonatal seizures, 4 MI receptors, 66 new drug application (NDA), 243, 246 Magnetic resonance spectroscopy nigrostriatal, 132 (MRS), 205, 206 nigrotectal GABA neurons, 133 mammillary bodies, 103, 104, 127 nigrotectal projection, 102 mammillary pedunc1es, 103 nigrotegmental, 132 mammillary system, 105 nigrothalamic, 132 Index 285 nipecotic acid, 64 pes hippocampi, 268 non-linear interaction, 51 PET scans, 199, 270 non-NMDA receptor, 173 petit mal, 5 nonstationarity, 43 phenobarbital, 239 nonstationarity detection, 40 phenytoin, 103, 177,224,225,227,228, no~inephrine,59,65,95,119, 170 229,240 nuclei,I04 Pi, 212 nucleus reticularis pontis oralis (RPO), picrotoxin, 92, 112, 170, 184, 240 117,143 picrotoxin receptors, 172 pilocarpine, 137, 138 occipitallobe seizures, 274 piriform, 260 occipital cortex, 19 pontine reticular formation, 117 occipital foci, 259 positive feedback, 57 olfactory sensations, 265 positron emission
Load more

Recommended publications
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan
    US008357723B2 (12) United States Patent (10) Patent No.: US 8,357,723 B2 Satyam (45) Date of Patent: Jan. 22, 2013 (54) PRODRUGS CONTAINING NOVEL "Nitric Oxide Donors and Cardiovascular Agents Modulating the BO-CLEAVABLE LINKERS Bioactivity of Nitric Oxide: An Overview” by Louis J. Ignarro, et al., Circulation Research, vol. 90, No. 1, pp. 21-22 (Jan. 11, 002). (75) Inventor: Apparao Satyam, Mumbai (IN) “Bis3-(4-substituted phenyl)prop-2-enedisulfides as a new class of (73) Assignee: Piramal Enterprises Limited and antihyperlipidemic compounds' by Meenakshi Sharma, et al., Apparao Satyam, Mumbai (IN) Bioorganic and Medicinal Chemistry Leters, vol. 14, No. 21, pp. (*) Notice: Subject to any disclaimer, the term of this 5347-5350 (Nov. 1, 2004). patent is extended or adjusted under 35 Abstract Only "Spectrophotometric determination of binary mix U.S.C. 154(b) by 0 days. tures of pseudoephedrine with some histamine H1-receptor antago nists using derivative radio spectrum method' by H. Mahgouh, et al., (21) Appl. No.: 12/977,929 J. Pham Biomed Anal, vol. 31, No. 4, pp. 801-809 Mar. 26, 2003. (22) Filed: Dec. 23, 2010 Peter D. Senter et al., Development of Drug-Release Strategy Based (65) Prior Publication Data on the Reductive Fragmentation pf Benzyl Carbamate Disulfides. Journal of Organic Chemistry, 1990, 55, 2975-2978. Published by US 2011 FO269709 A1 Nov. 3, 2011 American Chemical Society (USA). Related U.S. Application Data Vivekananda M. Virudhula et al., Reductively Activated Disulfide Prodrugs of Paclitaxel. Biorganic & Medicinal Chemistry Letters, (62) Division of application No. 1 1/213,396, filed on Aug.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Antiepileptic Drugs: Evolution of Our Knowledge and Changes in Drug Trials
    ILAE 110th anniversary review paper* Epileptic Disord 2019; 21 (4): 319-29 Antiepileptic drugs: evolution of our knowledge and changes in drug trials Emilio Perucca Past President of the International League Against Epilepsy Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia and IRCCS Mondino Foundation, Pavia, Italy Received April 30, 2019; Accepted June 01, 2019 ABSTRACT – Clinical trials provide the evidence needed for rational use of medicines. The evolution of drug trials follows largely the evolution of regulatory requirements. This article summarizes methodological changes in antiepileptic drug trials and associated advances in knowledge starting from 1938, the year phenytoin was introduced and also the year when evi- dence of safety was made a requirement for the marketing of medicines in the United States. The first period (1938-1969) saw the introduction of over 20 new drugs for epilepsy, many of which did not withstand the test of time. Only few well controlled trials were completed in that period and trial designs were generally suboptimal due to methodological constraints. The intermediate period (1970-1988) did not see the introduction of any major new medication, but important therapeutic advances took place due to improved understanding of the properties of available drugs. The value of therapeutic drug monitoring and monotherapy were recognized dur- ing the intermediate period, which also saw major improvements in trial methodology. The last period (1989-2019) was dominated by the introduc- tion of second-generation drugs, and further evolution in the design of monotherapy and adjunctive-therapy trials. The expansion of the pharma- cological armamentarium has improved opportunities for tailoring drug treatment to the characteristics of the individual.
    [Show full text]
  • P=.004), Comparable. Median Post-LT VPA-ALF Contraindicated for Acute
    and 76% were due to neurocysticercosis. (Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology April 12, 2011;76:1338-1343). (Response and reprints: Dr Sheffali Gulati, Department of Pediatrics, AIIMS, Ansari Nagar, New Delhi, 110 029, India. E-mail: [email protected] COMMENT. Gingival hyperplasia associated with phenytoin treatment of epilepsy is reported in as few as 3% of cases (Lennox WG, 1940) to as many as 78% (Gardner AF et al, 1962). It occurs more frequently in children than in adults. Numerous mechanisms have been proposed but few of proven significance. Other hydantoin anticonvulsants (mephenytoin, ethotoin, and albutoin) cause little or no gingival hyperplasia. The above investigators have discovered an important and correctable factor in the mechanism in their clinic population. The authors allude to a lack of dental hygiene in a high proportion of patients, a known contributing factor associated with tissue inflammation and irritation. Hyperplasia does not occur in edentulous adults. Phenytoin has an affinity for gingival tissue, and its effect on collagen and keratin in connective tissue has been used in the promotion of healing of wounds and leg ulcers (Shafer WG et al, 1958; Houck JC et al, 1972). In addition to man, only the ferret is susceptible to phenytoin gum hyperplasia, an interesting companion in science. Mechanisms largely disproven include a deficiency of ascorbic acid, adrenocortical dysfunction, and allergy (Gardner, 1962). Hyperglycemia induced by phenytoin, an effect discovered in our neurology research laboratories at Children's Memorial Hospital (Belton NR et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Issue #81-92, 1976
    ISSN 0090-1350 LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedical Communications Network No 81 January 197 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page Journal Citation Data Bases 2 On-line Technical Notes 2 Proposed Conversion from TSO to TCAM Message Handler As NLM's Teleprocessing Interface 5 Hedges , 9 Responsible Use of On-line Data Bases 11 An Experiment in On-Site Training, Madison, Wisconsin — December 15-19, 1975 12 Tumor Key Errata 14 MEDLINE Trainees at the University of Wisconsin, December 15, 1975 14 New Serials Announcement - December 1975 15 MEDLINE Trainees at NLM, January 12, 1976 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedlcal Communications Network JOURNAL CITATION DATA BASES EDITOR Grace H. McCarn Head, MEDLARS Management Section MEDLINE and SDILINS were updated with National Library of Medicine February 1976 citations at NLM and SUNY on 8600 Rockville Pike January 12. The sizes, Index Medicus date Bethesda, Maryland 20014 ranges, and entry date ranges are given (301) 496-6193 TWX: 710-824-9616 below: ASSISTANT EDITOR P.E. Pothier MEDLINE (Jan 74 - Feb 76) - 486,93? (Entry Dates: 731130 to 760102) TECHNICAL NOTES EDITOR Leonard J. Bahlman SDILINE (Feb 76) - 21,138 (Entry Dates: 751210 to 761012) The LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN is issued monthly by the Office of the Associate Director for Library Operations. ON-LINE TECHNICAL NOTES PLEASE QUERY THE NLM/ON-LINE NEWS FILES DAILY FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, in the margin beside each Technical Note., users will be referred to the section/page of the NLM On-Line Services Reference Manual which is considered most relevant to the item being discussed (e.g.., Manual II-9) .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Is Based Partly on a Stored Dictionary and Partly on the Identification of Text
    DOCUMENT RESUME ED 022 504 LI 000 909 By- Artandi, Susan; Baxenda!e, Stanley PROJECT MEDICO; MODEL EXPERIMENT IN DRUG INDEXING BY COMPUTER. FIRSTPROGRESS REPORT. Rutgers, The State Univ., New Brunswick, N.J. Graduate School of Library Service. Spons Agency-Public Health Service (DHEW), Washington, D.C. National Libraryof Medicine. Report No-PHS-LM-94 Pub Date Jan 68 Note- 1 1 1p. EDRS Price MF-$0.50 HC-1,452 Descriptors-*AUTOMATION, COMPUTER PROGRAMS, COMPUTERS, *COMPUTER STORAGE DEVICES, DICTIONARIES, *INDUING,*INFORMATIONRETRIEVAL,*INFORMATION STORAGE, INPUT OUTPUT, OPERATIONS RESEARCH, SEARCH STRATEGIES Identifiers- MEDIrCO, *Model Experiment in Drug Indexing by Computer This report describes Phase 1 of a research project with theover-all objective of exploring the applicability of automatic methods in theindexing of drug information appearing in English natural language text.Two major phases of the research have been completed:(1)development oftheautomaticindexing method andits implementation on the test documents and (2) creation of a machinesearchable file for the storage of the index records generated through automaticincicxing. Indexing is based partly on a stored dictionaryand partly on the identification of text characteristics which can be used to signal to the computerthe presence of information to be indexed. The characteristics of the machine file wereestablished with the desired search capabilities in mind. The file stores documentreferences with their associated index terms. In addition to assigning index terms todocuments the computer program also automatically assignsweights to the index terms to indicate their relative importance in the document 'description. The next two majorphases of the work will involve the design and implementation of the search programand the evaluation of the automatic indexing method.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,199,151 B2 Shashoua Et Al
    US007 1991.51B2 (12) United States Patent (10) Patent No.: US 7,199,151 B2 Shashoua et al. (45) Date of Patent: *Apr. 3, 2007 (54) DHA-PHARMACEUTICAL AGENT 4,692,441 A 9, 1987 Alexander et al. CONUGATES OF TAXANES 4,704,393 A 11/1987 Wakabayashi et al. 4,729,989 A 3, 1988 Alexander (75) Inventors: Victor E. Shashoua, Brookline, MA 4,788,063 A 11/1988 Fisher et al. (US); Charles E. Swindell, Merion, PA is: A RE s al (US); Nigel L. Webb, Bryn Mawr, PA 4s68161. A 9, 1989 Roberts (US); Matthews O. Bradley, 4.902,505 A 2/1990 Pardridge et al. Laytonsville, MD (US) 4,933,324. A 6/1990 Shashoua 4,939,174 A 7, 1990 Shashoua (73) Assignee: Luitpold Pharmaceuticals, Inc., 4,943,579 A 7, 1990 Vishnuvajala et al. Shirley, NY (US) 4,968,672 A 1 1/1990 Jacobson et al. 5,059,699 A 10/1991 Kingston et al. (*) Notice: Subject to any disclaimer, the term of this 5,068,224. A 11/1991 Fryklund et al. patent is extended or adjusted under 35 5, 112,596 A 5/1992 Malfroy-Camine U.S.C. 154(b) by 81 days. 5, 112,863 A 5/1992 Hashimoto et al. 5,116,624 A 5/1992 Horrobin et al. This patent is Subject to a terminal dis- 5, 120,760 A 6/1992 Horrobin claimer. 5,141,958 A 8, 1992 Crozier-Willi et al. 5,169,762 A 12/1992 Grey et al. (21) Appl. No.: 10/618,884 5,169,764 A 12/1992 Shooter et al.
    [Show full text]